Our study demonstrates that sorafenib treatment inhibits RhoE expression, thereby activating FAK in HCC cells, which leads to enhanced cholesterol biosynthesis and subsequent drug resistance. This evidence concerns the gene PTK2 and hepatocellular carcinoma.